Association of Treatment With Secukinumab With Exacerbation of Dermatomyositis in a Patient With Psoriasis

JAMA Dermatol. 2022 Apr 1;158(4):454-456. doi: 10.1001/jamadermatol.2021.6011.

Authors

Danielle L Perna^{1

2}, Jeffrey P Callen^{1

2}, Courtney R Schadt^{1

2}

Affiliations

¹ University of Louisville School of Medicine, Louisville, Kentucky.
² Division of Dermatology, University of Louisville, Louisville, Kentucky.

PMID: 35171205
DOI: 10.1001/jamadermatol.2021.6011

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Dermatomyositis* / complications
Dermatomyositis* / drug therapy
Double-Blind Method
Humans
Psoriasis* / complications
Psoriasis* / drug therapy
Severity of Illness Index
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
secukinumab